{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:29:58Z","timestamp":1790666998684,"version":"4.1.0"},"reference-count":136,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T00:00:00Z","timestamp":1557446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"DOI":"10.3389\/fped.2019.00178","type":"journal-article","created":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T10:08:56Z","timestamp":1557482936000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":55,"title":["Rituximab Use in the Management of Childhood Nephrotic Syndrome"],"prefix":"10.3389","volume":"7","author":[{"given":"Mahmoud","family":"Kallash","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Smoyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Mahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,5,10]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/ki.1978.23","article-title":"Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis","volume":"13","year":"1978","journal-title":"Kidney Int."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1186\/s12882-015-0208-0","article-title":"Time trends and ethnic patterns of childhood nephrotic syndrome in Yorkshire U.K","volume":"6","author":"McKinney","year":"2001","journal-title":"Pediatric Nephrol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3389\/fped.2016.00039","article-title":"Ethnic differences in childhood nephrotic syndrome","volume":"4","author":"Chanchlani","year":"2016","journal-title":"Front Pediatr."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1136\/adc.60.11.1014","article-title":"Steroid responsive nephrotic syndrome is more common in Asians","volume":"60","author":"Sharples","year":"1985","journal-title":"Arch Dis Childh."},{"key":"B5","first-page":"77","article-title":"Clinico-pathological features of the nephrotic syndrome in South African children","volume":"48","author":"Coovadia","year":"1979","journal-title":"Quar J Med."},{"key":"B6","unstructured":"Clinical Practice Guideline for Glomerulonephritis2012"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1097\/01.ASN.0000016406.82019.B3","article-title":"T cells and minimal change disease","volume":"13","author":"Cunard","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(03)14184-0","article-title":"Nephrotic syndrome in childhood","volume":"362","author":"Eddy","year":"2003","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/ki.1991.293","article-title":"T-lymphocyte subsets in nephrotic syndrome","volume":"40","author":"Fiser","year":"1991","journal-title":"Kidney Int"},{"key":"B10","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1046\/j.1523-1755.2000.00870.x","article-title":"Dominant T cells in idiopathic nephrotic syndrome of childhood","volume":"57","author":"Frank","year":"2000","journal-title":"Kidney Int."},{"key":"B11","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/nm.2411","article-title":"Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis","volume":"17","author":"Wei","year":"2011","journal-title":"Nat Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1681\/ASN.2012030302","article-title":"Circulating suPAR in two cohorts of primary FSGS","volume":"23","author":"Wei","year":"2012","journal-title":"J Am Soc Nephrol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1681\/ASN.2015050523","article-title":"B cell reconstitution after rituximab treatment in idiopathic nephrotic syndrome","volume":"27","author":"Colucci","year":"2016","journal-title":"J Am Soc Nephrol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1002\/art.38107","article-title":"Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response","volume":"65","author":"Melet","year":"2013","journal-title":"Arthr Rheumat."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1007\/s00296-015-3295-0","article-title":"Circulating CD4+ T-cell number decreases in rheumatoid patients with clinical response to rituximab","volume":"35","author":"Piantoni","year":"2015","journal-title":"Rheumatol Int."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1002\/art.38347","article-title":"Direct and indirect rituximab-induced T cell depletion: comment on the article by Melet et al","volume":"66","author":"Eggleton","year":"2014","journal-title":"Arthrit Rheumatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.autrev.2016.02.014","article-title":"New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: a prospective study and a review of the literature","volume":"15","author":"Roccatello","year":"2016","journal-title":"Autoimmunity Rev."},{"key":"B18","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.clim.2006.12.006","article-title":"Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis","volume":"123","author":"Sfikakis","year":"2007","journal-title":"Clin Immunol"},{"key":"B19","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1681\/ASN.V103529","article-title":"Th1 and Th2 cytokine mRNA profiles in childhood nephrotic syndrome: evidence for increased IL-13 mRNA expression in relapse","volume":"10","author":"Yap","year":"1999","journal-title":"J Am Soc Nephrol."},{"key":"B20","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2249.1995.tb03725.x","article-title":"Increased IL-2, IL-4 and interferon-gamma (IFN-gamma) in steroid-sensitive nephrotic syndrome","volume":"100","author":"Neuhaus","year":"1995","journal-title":"Clin Exp Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00467-004-1569-y","article-title":"Up-regulation of interleukin-2 mRNA in children with idiopathic nephrotic syndrome","volume":"19","author":"Shimoyama","year":"2004","journal-title":"Pediatr Nephrol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1681\/ASN.2006070710","article-title":"Overexpression of interleukin-13 induces minimal-change-like nephropathy in rats","volume":"18","author":"Lai","year":"2007","journal-title":"J Am Soc Nephrol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jaci.2007.11.016","article-title":"Anti-CD20 (rituximab) treatment improves atopic eczema","volume":"121","author":"Simon","year":"2008","journal-title":"J Aller Clin Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"85ra46","DOI":"10.1126\/scitranslmed.3002231","article-title":"Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis","volume":"3","author":"Fornoni","year":"2011","journal-title":"Sci Transl Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/nep.12737","article-title":"Rituximab protects podocytes and exerts anti-proteinuric effects in rat adriamycin-induced nephropathy independent of B-lymphocytes","volume":"22","author":"Takahashi","year":"2017","journal-title":"Nephrology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e013319","DOI":"10.1136\/bmjopen-2016-013319","article-title":"Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocol","volume":"7","author":"Ravani","year":"2017","journal-title":"BMJ Open"},{"key":"B27","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1007\/s00467-004-1434-z","article-title":"Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy","volume":"19","author":"Benz","year":"2004","journal-title":"Pediatr Nephrol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1053\/j.ajkd.2006.10.015","article-title":"Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in the adult: first case report and pathophysiological considerations","volume":"49","author":"Francois","year":"2007","journal-title":"Am J Kidney Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1007\/s00467-006-0228-x","article-title":"Rituximab therapy for steroid-dependent minimal change nephrotic syndrome","volume":"21","author":"Gilbert","year":"2006","journal-title":"Pediatr Nephrol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s00467-008-0814-1","article-title":"Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases, Pediatr Nephrol","volume":"23","author":"Guigonis","year":"2008"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.2215\/CJN.03470410","article-title":"Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report","volume":"5","author":"Gulati","year":"2010","journal-title":"Clin J Am Soc Nephrol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jaut.2017.10.006","article-title":"NEPHRUTIX: a randomized, double-blind, placebo vs Rituximab-controlled trial assessing T-cell subset changes in minimal change nephrotic syndrome","volume":"88","author":"Boumediene","year":"2018","journal-title":"J Autoimmun."},{"key":"B33","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00467-018-4133-x","article-title":"How to improve response to rituximab treatment in children with steroid-dependent nephrotic syndrome: answer to Drs","volume":"34","author":"Hogan","year":"2019","journal-title":"Pediatric Nephrol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s00467-017-3789-y","article-title":"Cost analysis on the use of rituximab and calcineurin inhibitors in children and adolescents with steroid-dependent nephrotic syndrome","volume":"33","author":"Iorember","year":"2018","journal-title":"Pediatric Nephrol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/MD.0000000000012704","article-title":"Comparison of the response of frequently relapsing steroid-dependent minimal change nephrotic syndrome to rituximab therapy between childhood-onset and adult-onset disease","volume":"97","author":"Iwabuchi","year":"2018","journal-title":"Medicine"},{"key":"B36","doi-asserted-by":"publisher","first-page":"257","DOI":"10.23876\/j.krcp.2017.36.3.257","article-title":"Long-term repeated rituximab treatment for childhood steroid-dependent nephrotic syndrome","volume":"36","author":"Kim","year":"2017","journal-title":"Kid Res Clin Prac."},{"key":"B37","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s00467-018-4172-3","article-title":"Low-dose rituximab is no less effective for nephrotic syndrome measured by 12-month outcome","volume":"34","author":"Maxted","year":"2018","journal-title":"Pediatric Nephrol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/ki.2013.211","article-title":"Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome","volume":"84","author":"Ravani","year":"2013","journal-title":"Kidney Int."},{"key":"B39","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00467-015-3245-9","article-title":"Cyclophosphamide and rituximab in frequently relapsing\/steroid-dependent nephrotic syndrome","volume":"31","author":"Webb","year":"2016","journal-title":"Pediatric Nephrol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"313","DOI":"10.5114\/ceji.2017.70976","article-title":"Effectiveness of rituximab in nephrotic syndrome treatment","volume":"42","author":"Popko","year":"2017","journal-title":"Cent Eur J Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s12519-014-0453-5","article-title":"Efficacy of rituximab therapy in children with refractory nephrotic syndrome: a prospective observational study in Shanghai","volume":"10","author":"Sun","year":"2014","journal-title":"World J Pediatr"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1681\/ASN.2014080799","article-title":"Rituximab in children with steroid-dependent nephrotic syndrome: a multicenter, open-label, noninferiority, randomized controlled trial","volume":"26","author":"Ravani","year":"2015","journal-title":"J Am Soc Nephrol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/jamapediatrics.2018.1323","article-title":"Efficacy of rituximab vs tacrolimus in pediatric corticosteroid-dependent nephrotic syndrome: a randomized clinical trial","volume":"172","author":"Basu","year":"2018","journal-title":"JAMA Pediatrics"},{"key":"B44","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3892\/br.2016.711","article-title":"Single dose of rituximab in children with steroid-dependent minimal change nephrotic syndrome","volume":"5","author":"Niu","year":"2016","journal-title":"Biomed Rep"},{"key":"B45","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00467-014-3034-x","article-title":"Positive role of rituximab in switching from cyclosporine to mycophenolate mofetil for children with high-dose steroid-dependent nephrotic syndrome","volume":"30","author":"Fujinaga","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s00467-010-1465-6","article-title":"Rituximab efficiency in children with steroid-dependent nephrotic syndrome","volume":"25","author":"Sellier-Leclerc","year":"2010","journal-title":"Pediatr Nephrol"},{"key":"B47","first-page":"521","article-title":"[Treatment of children with steroid-dependent nephrotic syndrome with rituximab]","volume":"52","author":"Huang","year":"2014","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"B48","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00467-009-1377","article-title":"Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine","volume":"25","author":"Fujinaga","year":"2010","journal-title":"Pediatr Nephrol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s00467-009-1191-0","article-title":"Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children","volume":"24","author":"Kamei","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1080\/17843286.2016.1208955","article-title":"Rituximab in children with steroid-dependent nephrotic syndrome: experience of a tertiary center and review of the literature","volume":"72","author":"Van","year":"2017","journal-title":"Acta Clin Belg"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1093\/ndt\/gfr548","article-title":"Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome","volume":"27","author":"Kemper","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"B52","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s00467-012-2406-3","article-title":"Long-term outcome of children treated with rituximab for idiopathic nephrotic syndrome","volume":"28","author":"Tellier","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.2215\/CJN.09421010","article-title":"Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial","volume":"6","author":"Ravani","year":"2011","journal-title":"Clin J Am Soc Nephrol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","article-title":"Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial","volume":"384","author":"Iijima","year":"2014","journal-title":"Lancet"},{"key":"B55","doi-asserted-by":"publisher","first-page":"e13157","DOI":"10.1097\/MD.0000000000013157","article-title":"Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: a multicenter open-label trial in Korea","volume":"97","author":"Ahn","year":"2018","journal-title":"Medicine"},{"key":"B56","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1681\/ASN.2013030251","article-title":"Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome","volume":"25","author":"Ruggenenti","year":"2014","journal-title":"JASN"},{"key":"B57","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1007\/s00467-017-3718-0","article-title":"Rituximab for childhood-onset refractory nephrotic syndrome (RCRNS) Study Group Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab","volume":"32","author":"Kamei","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"46036","DOI":"10.1038\/srep46036","article-title":"Cost-effectiveness of administering rituximab for steroid-dependent nephrotic syndrome and frequently relapsing nephrotic syndrome: a preliminary study in japan","volume":"7","author":"Takura","year":"2017","journal-title":"Sci Rep"},{"key":"B59","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1159\/000486941","article-title":"Socioeconomics of Administering Rituximab for Nephrotic Syndrome","volume":"195","author":"Takura","year":"2018","journal-title":"Contrib Nephrol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s00467-014-2792-9","article-title":"Impact of rituximab on height and weight in children with refractory steroid-dependent nephrotic syndrome","volume":"29","author":"Sato","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1681\/ASN.2011080775","article-title":"Rituximab in children with resistant idiopathic nephrotic syndrome","volume":"23","author":"Magnasco","year":"2012","journal-title":"J Am Soc Nephrol."},{"key":"B62","first-page":"27","article-title":"Efficacy and safety of rituximab in children with steroid- and cyclosporine-resistant and steroid- and cyclosporine-dependent nephrotic syndrome","volume":"12","author":"Hoseini","year":"2018","journal-title":"Iran J Kidney Dis"},{"key":"B63","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00467-007-0640-x","article-title":"Rituximab for refractory focal segmental glomerulosclerosis","volume":"23","author":"Nakayama","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1111\/ped.12948","article-title":"Efficacy of rituximab therapy against intractable steroid-resistant nephrotic syndrome","volume":"58","author":"Nakagawa","year":"2016","journal-title":"Pediatr Int."},{"key":"B65","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s11255-008-9393-0","article-title":"Remission of steroid-resistant nephrotic syndrome due to focal and segmental glomerulosclerosis using rituximab","volume":"40","author":"Suri","year":"2008","journal-title":"Int Urol Nephrol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/ped.12804","article-title":"Rituximab and low-dose cyclosporine combination therapy for steroid-resistant focal segmental glomerulosclerosis","volume":"58","author":"Suyama","year":"2016","journal-title":"Pediatr Int."},{"key":"B67","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00467-011-1778-0","article-title":"Rituximab for refractory cases of childhood nephrotic syndrome","volume":"26","author":"Kari","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1007\/s00467-014-2800-0","article-title":"Re-treatment with high-dose prednisolone after rituximab infusion for childhood-onset steroid-resistant nephrotic syndrome","volume":"29","author":"Fujinaga","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1056\/NEJMc063706","article-title":"Rituximab in patients with the steroid-resistant nephrotic syndrome","volume":"356","author":"Bagga","year":"2007","journal-title":"N Engl J Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/1440-1681.13046","article-title":"Multicenter analysis of the efficacy and safety of a non-standard immunosuppressive therapy with rituximab in children with steroid-resistant nephrotic syndrome","volume":"22","author":"Zachwieja","year":"2018","journal-title":"Clin Exp Pharmacol Physiol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00467-014-2765-z","article-title":"Rituximab treatment combined with methylprednisolone pulse therapy and immunosuppressants for childhood steroid-resistant nephrotic syndrome","volume":"29","author":"Kamei","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/ndt\/gfu267","article-title":"Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome","volume":"30","author":"Sinha","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-0486","article-title":"Mycophenolate mofetil following rituximab in children with steroid-resistant nephrotic syndrome","author":"Basu","year":"2015","journal-title":"Pediatrics"},{"key":"B74","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s00467-012-2319-1","article-title":"Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome","volume":"28","author":"Ito","year":"2013","journal-title":"Pediatr Nephrol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00467-009-1376-6","article-title":"Rituximab in refractory nephrotic syndrome","volume":"25","author":"Prytula","year":"2010","journal-title":"Pediatric Nephrol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1526-0968.2004.00164.x","article-title":"Effect of post-transplant double filtration plasmapheresis on recurrent focal and segmental glomerulosclerosis in renal transplant recipients","volume":"8","author":"Otsubo","year":"2004","journal-title":"Ther Apher Dial"},{"key":"B77","doi-asserted-by":"publisher","first-page":"3488","DOI":"10.1016\/j.transproceed.2007.09.045","article-title":"Recurrence of nephrotic proteinuria in children with focal segmental glomerulosclerosis after renal transplantation treated with plasmapheresis and immunoadsorption: case reports","volume":"39","author":"Fencl","year":"2007","journal-title":"Transplant Proc"},{"key":"B78","first-page":"348","article-title":"Recurrence of nephrotic proteinuria in children with focal segmental glomerulosclerosis: early treatment with plasmapheresis and immunoadsorption should be associated with better prognosis","volume":"68","author":"Fencl","year":"2016","journal-title":"Minerva Pediatr"},{"key":"B79","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/petr.12185","article-title":"Success withplasmapheresis treatment for recurrent focal segmentalglomerulosclerosis in pediatric renal transplant recipients","volume":"18","author":"Straatmann","year":"2014","journal-title":"Pediatr Transpl."},{"key":"B80","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12882-016-0322-7","article-title":"The role of plasma exchange in treating post-transplant focal segmental glomerulosclerosis: a systematic review and meta-analysis of 77 case-reports and case-series","volume":"17","author":"Kashgary","year":"2016","journal-title":"BMC Nephrol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1093\/ndt\/gfm616","article-title":"Post-transplant focal segmental glomerulosclerosis refractory to plasmapheresis and rituximab therapy","volume":"23","author":"El-Firjani","year":"2008","journal-title":"Nephrol Dial Transpl."},{"key":"B82","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1399-3046.2008.00967.x","article-title":"Ritixumab For Posttransplant Recurrences Of FSGS","volume":"13","author":"Baskin","year":"2009","journal-title":"Pediatr Transplant"},{"key":"B83","doi-asserted-by":"publisher","first-page":"E121","DOI":"10.1111\/j.1399-3046.2010.01303.x","article-title":"Long-term effect of rituximab in maintaining remission of recurrent and plasmapheresis-dependent nephrotic syndrome post-renal transplantation - case report","volume":"15","author":"Grenda","year":"2011","journal-title":"Pediatr Transplant"},{"key":"B84","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1007\/s10157-019-01690-0","article-title":"Successful management of post-transplant focal segmental glomerulosclerosis with therapeutic plasma exchange and rituximab","volume":"23","author":"Koutroutsos","year":"2019","journal-title":"Clin Exp Nephrol"},{"key":"B85","first-page":"408","article-title":"Rituximab in minimal change nephropathy and focal segmental glomerulosclerosis: report of four cases and review of the literature","volume":"66","author":"Peters","year":"2008","journal-title":"Neth J Med"},{"key":"B86","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s00467-012-2314-6","article-title":"Rituximab in post-transplant pediatric recurrent focal segmental glomerulosclerosis","volume":"28","author":"Kumar","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1007\/s00431-016-2747-1","article-title":"Rituximab is not a \u201cmagic drug\u201d in post-transplant recurrence of nephrotic syndrome","volume":"175","author":"Grenda","year":"2016","journal-title":"Eur J Pediatr"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1007\/s00467-015-3120-8","article-title":"Pharmacokinetics of rituximab in a pediatric patient with therapy-resistant nephrotic syndrome","volume":"30","author":"Counsilman","year":"2015","journal-title":"Pediatr Nephrol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jim.2017.09.001","article-title":"Detection and quantification of rituximab in the human urine","volume":"451","author":"Jacobs","year":"2017","journal-title":"J Immunol Methods"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1372859","DOI":"10.1155\/2017\/1372859","article-title":"Kinetics of rituximab excretion into urine and peritoneal fluid in two patients with nephrotic syndrome","volume":"2017","author":"Stahl","year":"2017","journal-title":"Case Rep Nephrol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00467-018-4139-4","article-title":"Idiopathic nephrotic syndrome and rituximab: may we predict circulating B lymphocytes recovery?","volume":"34","author":"Delbet","year":"2018","journal-title":"Pediatr Nephrol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"i306","DOI":"10.1093\/ndt\/gfy104.FP773","article-title":"Efficacy of two versus four doses of rituximab for childhood nephrotic syndrome","volume":"33","author":"Hahn","year":"2018","journal-title":"Nephrol Dial Transpl."},{"key":"B93","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00467-018-4063-7","article-title":"Periodically repeated rituximab administrations in children with refractory nephrotic syndrome: 2-year multicenter observational study","volume":"34","author":"Takahashi","year":"2019","journal-title":"Pediatric Nephrol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00467-018-4145-6","article-title":"Long-term outcomes after early treatment with rituximab for Japanese children with cyclosporine- and steroid-resistant nephrotic syndrome","volume":"34","author":"Fujinaga","year":"2019","journal-title":"Pediatric Nephrol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"E183","DOI":"10.1111\/j.1399-3046.2011.01519.x","article-title":"Rituximab treatment for recurrence of nephrotic syndrome in a pediatric patient after renal transplantation for congenital nephrotic syndrome of Finnish type","volume":"16","author":"Chaudhuri","year":"2012","journal-title":"Pediatr Transpl."},{"key":"B96","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00467-018-4052-x","article-title":"Effect of different rituximab regimens on B cell depletion and time to relapse in children with steroid-dependent nephrotic syndrome","volume":"34","author":"Hogan","year":"2019","journal-title":"Pediatric Nephrol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1007\/s00467-011-1894-x","article-title":"Should we consider MMF therapy after rituximab for nephrotic syndrome?","volume":"26","author":"Filler","year":"2011","journal-title":"Pediatric Nephrol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1007\/s00467-011-1886-x","article-title":"Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome","volume":"26","author":"Ito","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s00431-012-1913-3","article-title":"Cyclosporine versus mycophenolate mofetil for maintenance of remission of steroid-dependent nephrotic syndrome after a single infusion of rituximab","volume":"172","author":"Fujinaga","year":"2013","journal-title":"Eur J Pediatr"},{"key":"B100","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s10157-016-1328-y","article-title":"Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment","volume":"21","author":"Fujinaga","year":"2017","journal-title":"Clin Exp Nephrol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/s12882-018-1099-7","article-title":"Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07)","volume":"19","author":"Horinouchi","year":"2018","journal-title":"BMC Nephrol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1186\/s12882-018-1177-x","article-title":"Monitoring suPAR levels in post-kidney transplant focal segmental glomerulosclerosis treated with therapeutic plasma exchange and rituximab","volume":"19","author":"Alachkar","year":"2018","journal-title":"BMC Nephrol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s13075-016-1190-z","article-title":"Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis","volume":"18","author":"Sellam","year":"2016","journal-title":"Arthr Res Ther."},{"key":"B104","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12974-016-0648-x","article-title":"Circulating microRNAs as biomarkers for rituximab therapy, in neuromyelitis optica (NMO)","volume":"13","author":"Vaknin-Dembinsky","year":"2016","journal-title":"J Neuroinflam."},{"key":"B105","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1002\/art.30233","article-title":"B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study","volume":"63","author":"Sellam","year":"2011","journal-title":"Arthr Rheumat."},{"key":"B106","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/cei.12481","article-title":"Usefulness of monitoring of B cell depletion in rituximab-treated rheumatoid arthritis patients in order to predict clinical relapse: a prospective observational study","volume":"180","author":"Trouvin","year":"2015","journal-title":"Clin Exp Immunol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1002\/art.30466","article-title":"B cell biomarkers of rituximab responses in systemic lupus erythematosus","volume":"63","author":"Vital","year":"2011","journal-title":"Arthr Rheumat."},{"key":"B108","doi-asserted-by":"publisher","first-page":"e229","DOI":"10.1097\/MD.0000000000000229","article-title":"Prolonged B cell depletion with rituximab is effective in treating refractory pulmonary granulomatous inflammation in granulomatosis with polyangiitis (GPA)","volume":"93","author":"Henderson","year":"2014","journal-title":"Medicine"},{"key":"B109","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13075-017-1306-0","article-title":"B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients","volume":"19","author":"Thiel","year":"2017","journal-title":"Arthr Res Ther"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1093\/ndt\/gfr405","article-title":"Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood\u2013follow-up after CD19 recovery","volume":"27","author":"Sellier-Leclerc","year":"2012","journal-title":"Nephrol. Dial Transpl."},{"key":"B111","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.ekir.2017.11.004","article-title":"Combination therapy with rituximab and cyclophosphamide for remission induction in ANCA vasculitis","volume":"3","author":"Cortazar","year":"2018","journal-title":"Kidney Int Rep."},{"key":"B112","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s10157-017-1415-8","article-title":"Relapse of nephrotic syndrome during post-rituximab peripheral blood B-lymphocyte depletion","volume":"22","author":"Sato","year":"2018","journal-title":"Clin Exp Nephrol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1111\/bcp.13548","article-title":"Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome","volume":"84","author":"Bonanni","year":"2018","journal-title":"Br J Clin Pharmacol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s00467-018-3900-z","article-title":"Infusion reactions associated with rituximab treatment for childhood-onset complicated nephrotic syndrome","volume":"33","author":"Kamei","year":"2018","journal-title":"Pediatr Nephrol."},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2015-212694","article-title":"A mild form of rituximab-associated lung injury in two adolescents treated for nephrotic syndrome","author":"Spatafora","year":"2015","journal-title":"BMJ case Rep"},{"key":"B116","doi-asserted-by":"publisher","first-page":"E115","DOI":"10.1111\/petr.12481","article-title":"Fatal rituximab-associated lung injury syndrome in a patient treated with rituximab for recurrence of post-transplant nephrotic syndrome","volume":"19","author":"Grenda","year":"2015","journal-title":"Pediatr Transplant"},{"key":"B117","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s13730-017-0297-7","article-title":"Serum sickness with refractory nephrotic syndrome following treatment with rituximab","volume":"7","author":"Maeda","year":"2018","journal-title":"CEN Case Rep."},{"key":"B118","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1056\/NEJM200306263482620","article-title":"Neutropenia in patients treated with rituximab","volume":"348","author":"Voog","year":"2003","journal-title":"N Engl J Med."},{"key":"B119","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1097\/MD.0b013e3181f2caef","article-title":"Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature","volume":"89","author":"Wolach","year":"2010","journal-title":"Medicine"},{"key":"B120","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s13730-018-0364-8","article-title":"Crohn's disease following rituximab treatment in a patient with refractory nephrotic syndrome","volume":"8","author":"Morita","year":"2019","journal-title":"CEN Case Rep"},{"key":"B121","doi-asserted-by":"publisher","first-page":"e243","DOI":"10.1542\/peds.2009-3395","volume":"126","author":"Ardelean","year":"2010","journal-title":"Severe ulcerative colitis after rituximab therapy. Pediatrics"},{"key":"B122","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s13730-017-0264-3","article-title":"Acute demyelinating neuropathy associated with rituximab treatment in a patient with relapsing nephrotic syndrome","volume":"6","author":"Galassi","year":"2017","journal-title":"CEN Case Rep."},{"key":"B123","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00467-012-2286-6","article-title":"Atypical Pneumocystis jiroveci pneumonia with multiple nodular granulomas after rituximab for refractory nephrotic syndrome","volume":"28","author":"Sato","year":"2013","journal-title":"Pediatr Nephrol."},{"key":"B124","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s00467-013-2457-0","article-title":"Difficulties in diagnosing severe Pneumocystis jiroveci pneumonia after rituximab therapy for steroid-dependent nephrotic syndrome","volume":"28","author":"Czarniak","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1007\/s00467-013-2485-9","article-title":"inant viral myocarditis after rituximab therapy in pediatric nephrotic syndrome","volume":"28","author":"Sellier-Leclerc","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1517\/14740338.4.3.599","article-title":"Reactivation of hepatitis B virus with rituximab","volume":"4","author":"Tsutsumi","year":"2005","journal-title":"Expert Opin Drug safety"},{"key":"B127","doi-asserted-by":"publisher","first-page":"AB196","DOI":"10.1016\/j.jaci.2012.12.1366","article-title":"Persistent hypogammaglobulinemia after rituximab treatment","volume":"196","author":"Yelena","year":"2013","journal-title":"J Allergy Clin Immunol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","article-title":"Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease","volume":"57","author":"Roberts","year":"2015","journal-title":"J Autoimmun"},{"key":"B129","doi-asserted-by":"publisher","first-page":"340","DOI":"10.5414\/CN108835","article-title":"Late-onset adverse events after a single dose of rituximab in children with complicated steroid-dependent nephrotic syndrome","volume":"85","author":"Fujinaga","year":"2016","journal-title":"Clin Nephrol"},{"key":"B130","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1093\/ckj\/sfw101","article-title":"Infectious complications of a rituximab-based immunosuppressive regimen in patients with glomerular disease","volume":"10","author":"Trivin","year":"2017","journal-title":"Clin Kidney, J."},{"key":"B131","first-page":"49","article-title":"Repeated administrations of rituximab along with steroids and immunosuppressive agents in refractory steroid-resistant","volume":"54","author":"Fujinaga","year":"2017","journal-title":"Nephrotic Syndr."},{"key":"B132","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1007\/s00467-014-2794-7","article-title":"Development of antirituximab antibodies in children with nephrotic syndrome","volume":"29","author":"Ahn","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/cc11304","article-title":"Clinical review: serious adverse events associated with the use of rituximab - a critical care perspective","volume":"16","author":"Kasi","year":"2012","journal-title":"Crit Care"},{"key":"B134","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3339\/jkspn.2012.16.2.138","article-title":"Kikuchi-Fujimoto disease,. a possible complication of rituximab treatment","volume":"16","author":"Lee","year":"2012","journal-title":"J Kor Soc Pediatr Nephrol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1002\/art.23059","article-title":"Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis","volume":"56","author":"Keystone","year":"2007","journal-title":"Arthrit Rheumat."},{"key":"B136","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s00280-009-1062","article-title":"Intestinal perforation associated with rituximab therapy for post-transplant lymphoproliferative disorder after liver transplantation","volume":"64","author":"Cornejo","year":"2009","journal-title":"Cancer Chemother Pharmacol."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fped.2019.00178\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T17:00:51Z","timestamp":1663434051000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fped.2019.00178\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,10]]},"references-count":136,"alternative-id":["10.3389\/fped.2019.00178"],"URL":"https:\/\/doi.org\/10.3389\/fped.2019.00178","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,10]]},"article-number":"178"}}